Squarepoint’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Squarepoint’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-950	Closed	-$64K	–	3117
2020 Q4	$64K	Buy	+950	New	+$129K	﹤0.01%	2781

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Squarepoint's BCLI Position: Q1 2021 in Review

Squarepoint sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 950 shares — an estimated $64K sold.

Squarepoint first reported a position in BCLI in Q4 2020 and held it in 1 quarter. The position peaked at $64K in Q4 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

Squarepoint reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
Squarepoint sold 950 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $64K.
Squarepoint first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 1 quarter.
Squarepoint's BRAINSTORM CELL THERAPUTC position peaked at $64K in Q4 2020.
75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.